Talphera, Inc. (NASDAQ:TLPH) Short Interest Down 38.1% in September

Talphera, Inc. (NASDAQ:TLPH) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totalling 52,400 shares, a decrease of 38.1% from the August 31st total of 84,700 shares. Approximately 0.3% of the company’s stock are short sold. Based on an average daily volume of 58,700 shares, the short-interest ratio is presently 0.9 days.

Institutional Trading of Talphera

An institutional investor recently bought a new position in Talphera stock. Nantahala Capital Management LLC purchased a new position in Talphera, Inc. (NASDAQ:TLPH) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,992,519 shares of the company’s stock, valued at approximately $1,773,000. Nantahala Capital Management LLC owned about 11.73% of Talphera at the end of the most recent quarter. 37.67% of the stock is currently owned by hedge funds and other institutional investors.

Talphera Trading Up 6.1 %

NASDAQ:TLPH traded up $0.05 during trading hours on Friday, hitting $0.86. The stock had a trading volume of 54,034 shares, compared to its average volume of 88,383. The company has a market cap of $14.60 million, a PE ratio of -0.94 and a beta of 0.33. The business has a 50 day simple moving average of $0.92 and a two-hundred day simple moving average of $0.98. Talphera has a 1-year low of $0.43 and a 1-year high of $1.61.

Talphera (NASDAQ:TLPH) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. Research analysts expect that Talphera will post -0.73 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Talphera in a research note on Friday, August 16th.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.